Quality performance for indirect Xa inhibitor monitoring in patients using international external quality data
| Autor: | Felix J. M. van der Meer, Martine J Hollestelle, Piet Meijer |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Quality Control
medicine.medical_specialty Danaparoid Sodium Coefficient of variation Clinical Biochemistry Urology Dermatan Sulfate 030204 cardiovascular system & hematology Fondaparinux 03 medical and health sciences 0302 clinical medicine External quality assessment Humans Medicine business.industry Chondroitin Sulfates Biochemistry (medical) General Medicine Gold standard (test) Heparin Heparin Low-Molecular-Weight 030228 respiratory system Data quality Heparitin Sulfate Analysis of variance Drug Monitoring business Blood Chemical Analysis Factor Xa Inhibitors medicine.drug |
| Zdroj: | Clinical Chemistry and Laboratory Medicine (CCLM). 58:1921-1930 |
| ISSN: | 1437-4331 1434-6621 |
| Popis: | Objectives Chromogenic anti-activated factor X (FXa) assays are currently the “gold standard” for monitoring indirect anticoagulants. However, anti-FXa has been shown to vary according to the choice of reagents. In the present study, the performance of anti-FXa measurement was evaluated in order to gain more insight into the clinical applications. Furthermore, the longitudinal coefficient of variation (CV) was studied to investigate whether there is improvement over time. Methods Laboratory tests results were evaluated for samples spiked with unfractionated heparin (UFH), low-molecular-weight-heparin (LMWH), fondaparinux and danaparoid sodium. External quality assessment (EQA) data from multiple years were used from more than 100 laboratories. Results Comparison of the results for all methods showed significant differences in measured values between the frequently used methods (ANOVA: p Conclusions Our study demonstrates that the choice of the anti-FXa method is particularly important for UFH and LMWH measurement. The variation in measurements may have an effect on clinical implications, such as therapeutic ranges. Furthermore, the longitudinal EQA data demonstrated a constant performance and, in at least 50% of the cases, improvement in the CV% of the anti-Xa results over time. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|